Evidence map›Paper›PMID 39290241›Full record

ArticleFrontiers in oncology2024

The burden of liver cancer in Mongolia from 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.

Oyundari Batsaikhan, Odgerel Chimed-Ochir, Tatsuhiko Kubo, Chinburen Jigjidsuren, Vanya Delgermaa, Anuzaya Purevdagva, Amarzaya Sarankhuu, Erdenekhuu Nansalmaa, Uranchimeg Tsegmed, Badral Davgasuren and 6 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Oyundari Batsaikhan *Department of Public Health and Health Policy, Hiroshima University, Hiroshima, Japan.
Odgerel Chimed-Ochir *Department of Public Health and Health Policy, Hiroshima University, Hiroshima, Japan.
Tatsuhiko KuboDepartment of Public Health and Health Policy, Hiroshima University, Hiroshima, Japan.
Chinburen JigjidsurenState Great Hural, Parliament of Mongolia, Ulaanbaatar, Mongolia.
Vanya DelgermaaIndependent Researcher, Ulaanbaatar, Mongolia.
Anuzaya PurevdagvaCommunicable Diseases, World Health Organization (WHO), Ulaanbaatar, Mongolia.
Amarzaya SarankhuuMongolian Field Epidemiologists Society, Ulaanbaatar, Mongolia.
Erdenekhuu NansalmaaNational Cancer Center of Mongolia, Ulaanbaatar, Mongolia.
Uranchimeg TsegmedNational Cancer Center of Mongolia, Ulaanbaatar, Mongolia.
Badral DavgasurenInfectious Diseases Surveillance and Research Department, National Center for Communicable Diseases, Ulaanbaatar, Mongolia.
Oyuntsetseg PurevDepartment of Policy Planning, Ministry of Health, Ulaanbaatar, Mongolia.
Ali H MokdadInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, United States.
Nicole Davis WeaverInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, United States.
Ryenchindorj ErkhembayarDepartment of International Cyber Education, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
Christopher J L MurrayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, United States.
Mohsen NaghaviInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, United States.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background: Liver cancer remains the leading cause of death and public health threat among the Mongolian population. So far, there has been no in-depth analysis to describe the burden of common attributable factors to liver cancer in Mongolia. Therefore, we aimed to explore the most prevalent causes of liver cancer and its trends from 1990 to 2019. Methods: We extracted the primary liver cancer data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to examine the mortality and morbidity of liver cancer by its etiological types, which included alcohol, viral hepatitis B and C, and non-alcoholic steatohepatitis (NASH). The data was extracted by sex and 5-year age intervals from 1990 to 2019. Data included mortality, incidence, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) of liver cancer among the Mongolian population. Results: Mongolia had the world's highest age-standardized DALYs for liver cancer (2558.1) in 2019. Alcohol-attributable DALYs (786.6) were 29 times higher than the global average (26.1), and liver cancer due to hepatitis C (752.6) and B (763.2) were 21.5 (35.0) and 10.9 (69.1) times higher, respectively. Over the past 30 years, there has been a steady increase in the incidence and number of deaths caused by liver cancer in Mongolia. In 2019, liver cancer incidence due to alcohol consumption was 3.1 times higher for males than females, and hepatitis B was 2.7 times higher for males than females. However, the incidence of hepatitis C and NASH were slightly higher for females. Deaths from liver cancer accounted for 9.51% (2365) of total deaths in Mongolia in 2019, with a continuously increasing trend in the fraction of death compared to 1990, which was 11 times higher than the global average (0.86%), particularly in females with a 319.6% (95% UI 234.9-435.7) increase observed during the study period. Liver cancer due to hepatitis B, C, and alcohol each shared about one-third of liver cancer deaths. Conclusion: A comprehensive analysis of the burden of liver cancer in Mongolia reveals alcohol use as a primary cause of liver cancer mortality, particularly affecting men and significantly impacting the disease burden. Viral hepatitis continues to pose a major public health concern in the country. Although significant milestones have progressed, addressing the unique demographic and geographical challenges requires tailored approaches for specific target populations. The evidence generated from this analysis is crucial to support policy guidance, contribute to evidence-based decisions, guide public health prevention measures, and amplify population health promotion and disease prevention throughout Mongolia.

Indexed as

alcoholGBDhepatitis Bhepatitis Cliver cancer (LC)viral hepatitis

Identifiers

PMID39290241
PMCPMC11405307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.